Rockcliffe Labs Launches Canada’s First Venture-Building Platform for Biotechnology and Life Sciences with Mission to Create 100 CompaniesTORONTO, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Rockcliffe Labs Inc. (“Rockcliffe Labs”), a Canadian biotechnology venture creation platform, announces the launch of its first dedicated program designed to transform breakthrough scientific discoveries into scalable companies. This launch establishes Rockcliffe Labs as the first institution of its kind in Canada, with a mandate to create 100 biotechnology and life sciences ventures over the next decade.
Rockcliffe Labs Launches $75 Million Canadian Development Financing at $10 per Share, Reflecting $300 Million Post-Money Valuation; Executes License with a Canadian University for a Late-Stage Sepsis Biomarker–Based ProgramTORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Rockcliffe Labs Inc. (“Rockcliffe Labs” or the “Company”), a Canadian biotechnology venture creation platform, announces the launch of a $75 million non-brokered private placement in Canada (the “Offering”) at $10.00 per common share. The Offering reflects a post-money valuation of approximately $300 million and is structured as the development financing contemplated under Rockcliffe Labs’ license term sheet with a Canadian university.
